The latest price of Capmatinib in 2024 published on the entire network

Introduction: Capmatinib is a drug used to treat adults with advanced non-small cell lung cancer (NSCLC). This cancer has a specific genetic mutation in the cells that causes mesenchymal epithelial transition factor gene exon 14 (METex14) skipping. This means that the cancer cells produce an abnormal form of a protein called MET because a part of the MET gene (called exon 14) is not used.

The latest price of Capmatinib in 2024 announced on the entire website

There are many versions, including original research version and generic version. Currently, we know the prices of 1 original research version and 2 generic versions of Capmatinib.

1. Original research version: In the U.S. market, the reference price of capmatinib is approximately US$9,894 per box, which is approximately $71,684 in RMB based on the current exchange rate.

2. Generic version: The price of the generic version of capmatinib produced by Lucius Pharmaceuticals in Laos is about 2650$-3300$, and the specification of a box is about 200mgx60 tablets. The price of capmatinib, which is produced by Bangladesh Everest, is about 3,600$-4,000$, and the size of a box is about 200mg*56 tablets.

How capmatinib works

MET protein belongs to the receptor tyrosine kinase family and is involved in cell growth. In NSCLC patients with "METex14 skipping", an abnormal form of MET protein is produced, causing cancer cells to divide and grow in an uncontrolled manner. The active substance in capmatinib, capmatinib, is a receptor tyrosine kinase inhibitor that attaches to this abnormal MET protein in cancer cells, blocking the action of MET and helping to slow the growth and spread of cancer.

How to use Capmatinib

Capmatinib is available by prescription only, and treatment should be started and supervised by a doctor experienced in using anticancer drugs. Before starting treatment, patients should undergo testing to confirm the presence of METex14 skipping mutations in their cancer. Capmatinib is available as an oral tablet. The recommended dose is 400 mg twice daily, and patients can continue taking capmatinib for as long as they benefit from it. If certain side effects occur, your doctor may decide to reduce your dose, or interrupt or stop treatment with capmatinib.